Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

• Váldodahkkit: Julie A. Vendrell (Dahkki), Jérôme Solassol (Dahkki), Balázs Győrffy (Dahkki), Paul Vilquin (Dahkki), Marta Jarlier (Dahkki), Caterina F. Donini (Dahkki), Laurent Gamba (Dahkki), Thierry Maudelonde (Dahkki), Philippe Rouanet (Dahkki), Pascale A. Cohen (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2019-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positi...